Verona Pharma’s ensifentrine meets COPD objectives
Therapy shows quality of life boost and significant improvement in lung function
Read More
Tag: Verona
Verona’s ensifentrine meets primary endpoint
Chronic obstructive pulmonary disease phase 3 study shows statistically significant improvements in lung function
Read More
Verona Pharma’s ensifentrine heads for phase 3 chronic obstructive pulmonary disease trial
The company completes its enrolment in phase 3 trial evaluating ensifentrine for treatment of COPD
Read More
Verona progresses PhII trial of COPD inhaler
Following a pause because of coronavirus, the company has now kicked off the second part of a trial assessing a pressurised metered-dose inhaler formulation of ensifentrine
Read More
Verona Pharma share positive ensifentrine results in COPD
The trial consisted of 37 patients with moderate-to-severe COPD, who received a single dose of either the drug or a placebo.
Read More
Another EU patent for Verona in COPD drug
The patent further strengthens Verona Pharma’s intellectual property estate.
Read More
Verona initiates Phase II trial for COPD powder inhaler
Verona has announced the start of a Phase II clinical trial to evaluate a dry powder inhaler formulation of RPL554 in patients with moderate to severe chronic obstructive pulmonary disease.
Read More
- Ipsen announces new data on Dysport in neurological disease
- PMGroup Worldwide Ltd welcomes MAD World Summit
- Argenx receives review from FDA for VYVGART in seronegative gMG
- Nuclera extends Series C funding to advance antibody engineering
- Cellistic launches new iPSC-based platforms to expand immuno-oncology therapies
